reason report
rais austedo sale analysi posit medacorp
bottom line rais estim austedo base
analysi result latest edit
medacorp physician survey tardiv dyskinesia td
huntington chorea hc market point survey
physician continu prefer nr ingrezza austedo
gain experi product physician see
two compar compar result past two
survey edit done see posit trend support greater
util vesicular monoamin inhibitor
td physician continu cite insur coverag issu
austedo ingrezza new austedo
put us high end street base analysi
survey increas austedo revenu
rais austedo sale
pleas see teva note publish today rais
estim favor near-term trend teva still look
expens link remain teva pt
market td continu expand physician
gain experi austedo ingrezza overal
trend posit ingrezza austedo td
survey physician view td patient candid
higher septemb survey
januari survey analysi subset physician
particip septemb may survey suggest
smaller increas increas nevertheless model
percentag td patient candid inhibitor
middl two report rate believ
physician experi improv appetit prescrib
could continu get increment better time
physician start put austedo even competit
level ingrezza td rais td sale estim
peak market share mix ingrezza
austedo improv recent survey
septemb survey attribut grow
physician experi austedo td support previou
medacorp specialist feedback overal austedo ingrezza
similar differ
still see hc small sale opportun
austedo due slightli favor profil tetrabenazin even
though austedo market year physician
continu use tetrabenazin major patient note
reimburs remain key reason use austedo longer term
expect austedo captur major categori
split tetrabenazin
ev/ebitda multipl
ebitda
net debt total capit
gener unless otherwis note
compani inform leerink partner llc research
revenu adjust non-gaap ep present
pleas refer page import disclosur price chart analyst certif
rais total austedo sale driven
higher sale td partial off-set lower sale hc chang
made market model includ increas percentag td
patient candid inhibitor
increas peak percentag td patient treat
inhibitor increas peak austedo share
repres nbix/teva
split believ highlight grow sentiment among physician
gain experi ingrezza austedo product
compar differ lower peak austedo share hc
continu insid full survey takeaway
medacorp physician survey indic greater opportun austedo
tardiv dyskinesia partial off-set smaller opportun huntington
believ teva remain pressur due overhang long approv fremanezumab
delay continu headwind copaxon sandoz nv gener potenti
other sale declin us gener outer year believ consensu
underestim rate teva under-perform price target
ebitda ev/ebitda multipl drive teva lower view pt
risk valuat
higher-than-expect number new gx launch lower-than-expect number competitor copaxon key
brand product austedo fremanezumab perform expect
increas austedo number
due expand tardiv dyskinesia opportun
revis estim assum significantli larger opportun austedo tardiv
dyskinesia partial off-set lower market share austedo huntington chorea
higher util td primari driver higher austedo estim
driver model chang
impact austedo sale
td patient
candid inhibitor
inhibitor
share td
td
hc
import disclosur analysi
previous commiss medacorp physician survey center opportun teva austedo
nbix nr ingrezza tardiv dyskinesia td space iter survey sinc
previou version jan sept note highlight key takeaway latest
survey particular physician view chang time
includ prior medacorp survey look physician respons across three differ timepoint
januari month prior fda approv ingrezza first treatment option tardiv dyskinesia
septemb ingrezza market month austedo recent receiv fda
approv tardiv dyskinesia
may product fda approv tardiv dyskinesia month
unlik previou iter survey includ physician current prescrib inhibitor
teva austedo nbix ingrezza tetrabenazin patient tardiv dyskinesia contrast
septemb survey respond current prescrib inhibitor
acknowledg limit util survey current prescrib believ survey result
better repres patient popul
medacorp survey neurologist psychiatrist treat
patient td patient huntington chorea hc
screener mani patient tardiv dyskinesia
person treat see least per year
clinic specialti physician survey
screener neurolog mani patient
treat huntington chorea
slight decreas td preval rate impli survey
still sizeabl segment market
question proport patient treat
atyp typic antipsychot develop tardiv dyskinesia
patient treat atyp antipsychot go develop
patient treat typic antipsychot go develop tardiv
patient treat atyp antipsychot go develop
patient treat typic antipsychot go develop tardiv
continu util breakdown psychiatrist physician main
prescrib antipsychot like better indic real-world td rate
latest survey impli slight decreas td preval gener regard estim
consist report septemb survey
model decreas overal td preval rate slightli
base respons psychiatrist latest survey
note assum patient atyp
patient schizoaffect disord mdd bipolar still repres half
td market
question proport tardiv dyskinesia patient schizophrenia schizoaffect
disord major depress disord bipolar disord
proport td patient schizophrenia seem higher per
latest survey howev preval td still seem fairli signific
among schizoaffect disord mdd bipolar patient would
expect higher motiv seek treatment option td
current treatment option td show room improv none
older option stand clear winner
question proport patient develop td abl induc long-term
control dyskinesia keep underli condit schizophrenia bipolar
disord stabl via follow treatment approach
reduc dose
switch
antipsychot
therapi
classic agent
atyp
treatment
latest edit survey
requir physician use
td unlik past
version would expect
proport higher
consist ingrezza
austedo note
respons
written sept
survey one
two
increas
latest version
awar drug meaning increas sinc last survey
austedo push last month essenti driven psychiatrist
question current level awar novel inhibitor treatment td
austedo deutetrabenazin ingrezza valbenazin pleas select one product
well awar product investig clinic trial
well awar product data investig
heard drug awar clinic data
never heard drug
well awar product investig clinic trial
well awar product data investig
heard drug awar clinic data
never heard drug
well awar product investig clinic trial
well awar product data investig
heard drug awar clinic data
never heard drug
well awar product investig clinic trial
well awar product data investig
heard drug awar clinic data
never heard drug
physician project td patient candid
inhibitor although may partial influenc screen criteria
question proport tardiv dyskinesia patient
candid receiv inhibitor
unlik prior survey restrict respond current prescrib
td patient acknowledg like overst result question non
user would like assum lower proport td patient candid
therapi howev believ ingrezza austedo market month td
time appropri ensur product-specif respons base actual
survey question suggest increas assum
model reflect potenti impact chang target respond latest
dont know rate continu increas fast rate believ
posit trend time support belief product profil drug
drive util overal class
posit prescrib trend austedo ingrezza also suggest
new user oppos tetrabenazine-switch drive uptak
question mani total patient start inhibitor includ patient
discontinu treatment mani current treat
average patient
drug
average patient
total patient
last month
number
physician
remain larg
howev see
signific increas
number
prescrib
util
austedo ingrezza
appear support
previou slide
indic higher
patient candid
treat
td
greater clinic experi physician appear consid
efficaci two product compar
question clinic experi effect ingrezza austedo tetrabenazin td
hypothes sept survey austedo slightli disadvantag ingrezza
due recent approv td like slower onset action result titrat
requir month physician like better understand efficaci
product appear regard two product gener compar
major physician continu view benefit least
moder clinic signific ingrezza continu advantag
question clinic signific treatment benefit ingrezza valbenazin austedo
question overal ingrezza valbenazin
austedo deutetrabenazin product
prefer tardiv dyskinesia
physician commentari latest survey focus
safeti cost new class therapi
see natur consequ greater
util experi
efficaci feedback primarili highlight product
approv therapi td
also fewer physician note lack experi
take sign physician gone
least one go-around
ingrezza stronger profil vs austedo term efficaci
safety/toler conveni
question drug stronger efficaci safety/toler convenience/eas use
convenience/eas use
ingrezza continu prefer physician half
physician prefer across three featur
physician comment highlight number key point
dose ingrezza titrat simpler
ingrezza appear slightli better efficaci
physician regard two littl differenti
note lack direct comparison head-to-
head trial two product still
time physician experi influenc usag
ingrezza austedo slightli prefer tetrabenazin across
multipl featur insur coverag remain work progress
question inhibitor rate follow featur pleas rate
scale attract attract
onset
efficaci
question experi insur coverag access inhibitor
tardiv dyskinesia tetrabenazin ingrezza austedo pleas rate scale
free
experi insur coverag tetrabenazin td
experi insur coverag ingrezza valbenazin td
experi insur coverag austedo deutetrabenazin td
experi insur coverag tetrabenazin td
experi insur coverag ingrezza valbenazin td
experi insur coverag austedo deutetrabenazin td
may survey incorpor formulari approv denial ingrezza
austedo approv process continu compar tetrabenazin
interestingli last month ingrezza market presenc appear
reson strongli physician
question neurocrin ingrezza teva austedo stronger market presenc
would expect slight normal among psychiatrist
austedo approv indic interestingli neurologist
essenti equal split ingrezza austedo prefer howev
teva refocus busi place greater emphasi growth driver
austedo expect reson physician time
latest survey suggest lower share ingrezza although attribut
latest find physician option austedo td
question percent td patient would expect receiv follow treatment
month respect
lower share uptak
ingrezza
note
survey result like
overst vs actual
interest
month share
progress
austedo
note dash line repres impli estim septemb survey timepoint septemb
septemb
believ greater experi util austedo td physician
start regard product gener compar
question proport inhibitor treat td patient would expect
ingrezza valbenazin austedo deutetrabenazin tetrabenazin peak penetr maximum
percent td patient expect prescrib drug
note refer aggreg respons refer psychiatri
model increas tetrabenazin share slightli
howev also increas austedo share
repres ingrezza austedo split
impli survey final also rais peak
penetr
sum peak share
appli previou
peak penetr
septemb survey
model share split
ingrezza austedo
howev appear
follow month austedo
util td physician
comfort profil
drug
ingrezza/austedo split
believ peak tbz
share high due physician
make-up survey
tend academ
would greater comfort
share
half survey respond also particip sept
survey opinion subset physician chang
took look specif respons physician also particip
question proport tardiv dyskinesia
patient candid receiv inhibitor
question clinic signific treatment benefit
ingrezza valbenazin austedo deutetrabenazin
smaller increas among
subset physician suggest
physician consid
td patient
therapi increas larg
overal survey result
physician viewpoint
drug remain consist
ingrezza continu regard
slightli better treatment
fluctuat physician view attribut three drug
gener consist overal trend
took look specif respons physician also particip
question drug stronger efficaci
safety/toler convenience/eas use
question overal ingrezza valbenazin austedo
deutetrabenazin product prefer tardiv dyskinesia
physician appear
regard safeti
compar efficaci
conveni continu
due greater
experi austedo
td sept
drug
approv month
indic
physician might greater
comfort austedo profil
addit month util
subset physician follow
broader subtl shift view
product differenti
subset physician appear suggest larger improv
coverag access
took look specif respons physician also particip
question inhibitor prescrib
treatment tardiv dyskinesia
clearli physician use
austedo also ingrezza
come slightli expens
tetrabenazin support
increas use class
question experi insur coverag access
inhibitor tardiv dyskinesia tetrabenazin ingrezza
austedo pleas rate scale free
overal survey show less
improv insur coverag access
encourag benefit seen
suggest still much room
improv coverag access get
increment better time
despit deviat peak market share estim physician
encourag given rel split ingrezza austedo consist
took look specif respons physician also particip
question proport inhibitor treat td patient would expect
ingrezza valbenazin austedo deutetrabenazin tetrabenazin peak penetr
maximum percent td patient expect prescrib drug
interestingli peak share
assumpt ingrezza austedo
among subset physician
much lower
report physician overal
subset
physician know
experi util drug
would like temper
importantli note rel breakdown
ingrezza austedo
look either subset physician respons
hc physician overal believ austedo induc better control hc
tetrabenazin although physician believ product undifferenti
question compar clinic profil tetrabenazin believ clinic profil
austedo deutetrabenazin huntington chorea compar
austedo clearli
austedo margin
austedo
austedo margin
austedo clearli inferior
tetrabenazin
tetrabenazin
tetrabenazin
tetrabenazin
undifferenti one
tetrabenazin
question clinic experi effect austedo tetrabenazin huntington
induc control hc
induc control hc
induc control
patient receiv
patient receiv
hc
effect
treatment hc
patient receiv
product profil austedo tetrabenazin appear compar
austedo slightli better efficaci although insur coverag remain issu
question inhibitor compar one anoth treatment
huntington chorea follow pleas rate scale favor
physician commentari insur
character
prior failur tetrabenazin
potenti therapi
austedo usag
high cost therapi
two respons
onset
efficaci
product profil appear mostli compar physician appear
regard austedo potenti option patient discontinu tetrabenazin
question proport hd chorea patient start
tetrabenazin remain tetrabenazin month
remain treatment month
remain treatment month
remain treatment month
question would consid give austedo
tetrabenazine-discontinu patient
percent tetrabenazine-discontinu
patient prescrib austedo
question long expect huntington
chorea patient remain austedo
averag number month expect huntington chorea
patient remain austedo deutetrabenazin
patient tetrabenazin
appear discontinu treatment
month remain patient
stay treatment year
along fact physician
consid austedo potenti
treatment even tbz-discontinu
patient suggest still
potenti greater austedo util
month market reimburs remain key reason
patient get austedo
question pleas rate follow reason huntington chorea patient get austedo
treatment rate patient stop therapi earli pleas rate scale
import import
onset efficaci
efficaci manag
get austedo
overal doesnt appear specif reason hc patient stop austedo
earli howev reimburs appear key reason patient might get
austedo begin improv key penetr hc
feedback austedo hc suggest modest improv
tetrabenazin reflect physician estim peak market share
question percent hd chorea patient receiv austedo deutetrabenazin
xenazin tetrabenazin today mani would expect receiv austedo
deutetrabenazin xenazin tetrabenazin month respect pleas
assum gener version tetrabenazin avail time period
question peak penetr proport huntington chorea patient would
expect austedo deutetrabenazin xenazin tetrabenazin brand gener
despit year market
physician indic
continu use tetrabenazin
patient austedo
like due physician familiar
tetrabenazin
market year
lack signific benefit
model lower peak austedo share among
number respond
neurolog psychiatri
respons repres averag neurologist psychiatrist aggreg respons unless
screener best describ clinic specialti
screener mani patient schizophrenia schizoaffect disord major depress disord bipolar disord
person treat respect see least per year
screener mani patient tardiv dyskinesia person treat see least per year
number patient tardiv dyskinesia person treat see least
per year aggreg
number patient tardiv dyskinesia person treat see least
per year psychiatri
number patient tardiv dyskinesia person treat see least
per year neurolog
screener current prescrib inhibitor teva austedo deutetrabenazin neurocrin ingrezza
valbenazin tetrabenazin patient tardiv dyskinesia
screener neurolog mani patient treat huntington chorea
number patient huntington chorea person treat see least
per year neurolog
screener neurolog current prescrib inhibitor teva austedo deutetrabenazin
tetrabenazin patient huntington chorea
proport patient treat atyp typic antipsychot develop tardiv dyskinesia
patient treat atyp antipsychot go develop tardiv
patient treat typic antipsychot go develop tardiv
proport tardiv dyskinesia patient schizophrenia schizoaffect disord major depress
disord bipolar disord
patient tardiv dyskinesia schizophrenia
patient tardiv dyskinesia schizoaffect disord
patient tardiv dyskinesia major depress disord
patient tardiv dyskinesia bipolar disord
proport patient develop td abl induc long-term control dyskinesia
keep underli condit schizophrenia bipolar disord stabl via follow treatment approach
reduc dose antipsychot
switch differ antipsychot
treatment tetrabenazin
initi suppress therapi classic agent classic agent atyp
diazepam clonazepam clonazepam baclofen clonidin benzo
elimin antipsychot ingrezza ingrezza austedo
ingrezza control control stop med treatment
current level awar novel inhibitor treatment td austedo
deutetrabenazin ingrezza valbenazin pleas select one product
well awar product investig clinic trial
well awar product data investig
heard drug awar clinic data
never heard drug
well awar product investig clinic trial
well awar product data investig
heard drug awar clinic data
never heard drug
pleas review inform neurocrin ingrezza valbenazin teva austedo deutetrabenazin
ingrezza valbenazin austedo deutetrabenazin vesicular monoamin transport inhibitor
approv fda market treat tardiv dyskinesia phase trial compani demonstr
statist signific clinic benefit abnorm involuntari movement scale aim
ingrezza label pleas click http //ingrezzahcp com/pi
austedo label pleas click http //www austedo com/hcp/renderpdf aspx file prescribinginform pdf
proport tardiv dyskinesia patient candid receiv inhibitor
percent td patient candid receiv adjunct therapi
td
clinic signific treatment benefit ingrezza valbenazin austedo deutetrabenazin
highli clinic signific support use tardiv dyskinesia patient
candid adjunct therapi td
moder clinic signific support use tardiv dyskinesia
patient candid adjunct therapi td
margin clinic signific support use minor tardiv
dyskinesia patient candid adjunct therapi td
clinic signific support use tardiv dyskinesia patient
candid adjunct therapi td
appendix summari respons
highli clinic signific support use tardiv dyskinesia patient
candid adjunct therapi td
moder clinic signific support use tardiv dyskinesia
patient candid adjunct therapi td
margin clinic signific support use minor tardiv
dyskinesia patient candid adjunct therapi td
clinic signific support use tardiv dyskinesia patient
candid adjunct therapi td
drug stronger efficaci safety/toler convenience/eas use
convenience/eas use
appendix summari respons
overal ingrezza valbenazin austedo deutetrabenazin product prefer tardiv
prefer two drug appear undifferenti
inhibitor prescrib treatment tardiv dyskinesia check appli
mani total patient start inhibitor includ patient discontinu treatment
mani current treat
number patient start
number patient
number patient start
number patient
number patient start
number patient
experi insur coverag access inhibitor tardiv dyskinesia
tetrabenazin ingrezza austedo pleas rate scale free
experi insur coverag tetrabenazin td
experi insur coverag ingrezza valbenazin td
experi insur coverag austedo deutetrabenazin td
appendix summari respons
clinic experi effect ingrezza austedo tetrabenazin td control dyskinesia
induc control td patient receiv
induc control td patient receiv
induc control td patient receiv
effect treatment td
induc control td patient receiv
induc control td patient receiv
induc control td patient receiv
effect treatment td
induc control td patient receiv
induc control td patient receiv
induc control td patient receiv
effect treatment td
long expect td patient remain inhibitor
averag number month expect td patient remain ingrezza
averag number month expect td patient remain austedo
averag number month expect td patient remain tetrabenazin
inhibitor rate follow featur pleas rate scale
attract attract
onset efficaci
efficaci manag symptom
onset efficaci
efficaci manag symptom
onset efficaci
efficaci manag symptom
percent td patient would expect receiv follow treatment month
percent td patient receiv pharmacotherapi movement disord
proport inhibitor treat td patient would expect ingrezza valbenazin austedo
deutetrabenazin tetrabenazin peak penetr maximum percent td patient expect prescrib
drug
percent inhibitor treat td patient ingrezza valbenazin
percent inhibitor treat td patient austedo deutetrabenazin
peak penetr
percent inhibitor treat td patient tetrabenazin peak
expect peak penetr inhibitor td patient background schizophrenia versu
inhibitor penetr td patient schizophrenia
inhibitor penetr td patient mood disord mdd
neurocrin ingrezza teva austedo stronger market presenc
austedo teva stronger market presenc
ingrezza neurocrin stronger market presenc
mani patient treat tourett syndrom
number patient treat tourett mean
number patient treat tourett median
number patient treat tourett
ever use tetrabenazin treat tourett
proport tourett patient current take tetrabenazin
percent tourett patient current take tetrabenazin
compar efficaci profil tardiv dyskinesia effect medicin tetrabenazin treat tourett
effect tourett tardiv dyskinesia
similarli effect tourett tardiv dyskinesia
margin less effect tourett tardiv dyskinesia
tetrabenazin ineffect treat tourett syndrom
compar efficaci profil atyp antipsychot effect medicin tetrabenazin treat
tetrabenazin effect atyp antipsychot ts
tetrabenazin atyp antipsychot similarli effect ts
tetrabenazin less effect atyp antipsychot ts
tetrabenazin ineffect treat tourett syndrom
proport hd chorea patient candid receiv inhibitor
percent hd chorea patient candid receiv therapi hd
compar clinic profil tetrabenazin believ clinic profil austedo deutetrabenazin
austedo clearli superior tetrabenazin
austedo margin better tetrabenazin
austedo tetrabenazin undifferenti one anoth
austedo margin inferior tetrabenazin
austedo clearli inferior tetrabenazin
mani total patient start inhibitor includ patient discontinu treatment
mani current treat
number
total number patient
clinic experi effect austedo tetrabenazin huntington chorea
induc control huntington chorea patient receiv
induc control huntington chorea patient receiv
induc control huntington chorea patient receiv
effect treatment huntington chorea
induc control huntington chorea patient receiv
induc control huntington chorea patient receiv
induc control huntington chorea patient receiv
effect treatment huntington chorea
experi insur coverag access inhibitor huntington chorea
tetrabenazin austedo pleas rate scale free
experi insur coverag tetrabenazin huntington chorea free
experi insur coverag austedo huntington chorea free
pleas comment briefli specif criteria put place requir reimburs austedo
appendix summari respons
inhibitor compar one anoth treatment huntington chorea
follow pleas rate scale favor favor
onset efficaci
efficaci manag symptom
percent hd chorea patient receiv austedo deutetrabenazin xenazin tetrabenazin today
mani would expect receiv austedo deutetrabenazin xenazin tetrabenazin month
respect pleas assum gener version tetrabenazin avail time period
percent hd patient
month
novemb
month
may
month
may
tetrabenazin either brand gener
peak penetr proport huntington chorea patient would expect austedo
deutetrabenazin xenazin tetrabenazin brand gener
percent hc patient austedo deutetrabenazin peak penetr
percent hc patient xenazin tetrabenazin brand gener peak penetr
proport hd chorea patient start tetrabenazin remain tetrabenazin month
remain treatment month
remain treatment month
remain treatment month
would consid give austedo tetrabenazine-discontinu patient
percentag tetrabenazine-discontinu would give austedo
percent tetrabenazine-discontinu patient prescrib austedo
pleas rate follow reason huntington chorea patient get austedo treatment rate
patient stop therapi earli pleas rate scale import
get
onset efficaci
efficaci manag symptom
safeti concern includ box warn depress suicid
long expect huntington chorea patient remain austedo deutetrabenazin
averag number month expect huntington chorea patient remain austedo deutetrabenazin
appendix summari respons
question clinic signific treatment benefit ingrezza valbenazin austedo deutetrabenazin
prescrib ingrezza patient td good result less experienc austedo
mani dont want med may contraind
see much differ clinic
formulari avail huge factor
realli good altern address td
fewer patient present td current year ago treatment option cumbersom mani
barrier far appear worth effort
lack experi
partli im familiar ingrezza
advantag austedo ingrezza austedo need dose bid potenti cardiovascular
psychiatr side effect ingrezza
start use austedo
better use
expens valu improv qualiti life worst case
evid symptom function posit impact meaning signific degre
abil patient recov function walk eat dress valuabl
price remain activ issu treatment
replic trial phase iv trial need
patient benefit treatment
patient improv condit
heard data present last year
find highli effect well toler situat
limit experi thu far agent overal posit time abl say go
highli signific
td symptom mild reduc dose antipsychot may preclud need vmat inhibitor
similar modest efficaci
aim dyskinesia score lower trial patient global impress chang significantli differ
placebo
inhibitor tremend breakthrough
greater efficaci safeti tetrabenazin
drug show meaning reduct symptom td patient
clinic data show definit case moder improv
yet use austedo ingrezza repres treatment target underli mechan diseas
patient vastli efficaci littl toxic
similar efficaci ingrezza toler
still see drug work patient popul put stock publish evid prefer real
patient toler drug especi tetrabenazin analog effect dramat last
strong data
medic first line therapi td practic
effect treatment tardiv dyskinesia
effect td disabl symptom
help work everyon
austedo worsen mood disord ingrezza side effect less sever medic treat involuntari
help improv qualiti life
think new medic new treatment option tardiv dyskinesia
ive receiv variabl gener posit report
efficaci appear least equal current avail treatment approach
indic approv similar moa
question drug stronger efficaci safety/toler convenience/eas use specifi
easi get
similar
custom servic central hub pharmaci
question drug stronger efficaci safety/toler convenience/eas use pleas comment briefli
ingrezza help td though fatigu common side effect
better access
see much differ
patient afford import
experi ingrezza seen data realli differenti two
ingrezza daili contraind would make easier use ever figur
possibl im familiar ingrezza
use austedo outpati practic far
seem similar agent
differ emerg time
find differ
good safeti data would affect choic agent appear ingrezza may slightli better
efficaci ingrezza easier use
trial long term side effect need
work
prefer valbenazin eas use reason given paramet efficaci safeti wash
review time ago conclud ingrezza slightli better
find certain patient prefer one find similar efficaci
ingrezza qd wherea austedo bid qd increas complianc
austedo seem work better
main differ conveni daili vs twice daili dose
seem similar
drug similar featur
valbenazin seem margin better indirect comparison
austedo advantag flexibl also less straightforward dose
trial compar two drug
appear similarli effect
abl compar agent suspect littl separ two like
better toler compar xenazin
feel comfort ingrezza
still get feel work practic
publish data ingrezza seem strongli efficaci
caveat austedo win efficaci due wider dose rang low dose ingrezza effect
multipl patient fail ingrezza due lack efficaci better result go higher
higher dose austedo
ingrezza best mild moder td case
major issu time formulari avail
find ingrezza bit effect
feel equal efficaci
ingrezza suicid warn prefer
head head trial
although direct comparison studi perceiv ingrezza somewhat effect two treatment
convinc real differ
rel larger reduct base aim placebo direct comparison
less concern drug interact ingrezza
question experi insur coverag access inhibitor tardiv dyskinesia
tetrabenazin ingrezza austedo pleas rate scale free pleas
comment briefli specif criteria put place requir reimburs austedo and/or ingrezza
confirm diagnosi
lack respons mean treat td
rep help process
step therapi formulari
best psychopharmacolog opinion
gener tetrabenazin lowest co-pay
need show medic necess
label indic fail prior therapi
deleg admin staff institut
pt fail tetrabenazin
appeal char note
use least therapi prior
step therapy/mov scale greater
pa step therapi
failur tetrabenazin
inadequ respons drug includ axe axe aim score
tbz step one instanc ingrezza step
lack respons mean treat td
pa
specialti pharmaci sever symptom
inadequ respons drug aim score stop offend drug
failur tetrabenazin
confirm diagnosi
step therapi formulari
best psychopharmacolog opinion
gener tetrabenazin lowest co-pay
label indic fail prior therapi
deleg admin staff institut
pt fail tetrabenezin
appeal char note
use least therapi prior
requir step edit prior author
tbz step amantadin step
question pleas comment briefli specif criteria put place requir reimburs austedo
one patient insur requir first tri tetrabenazin prior austedo
tbz step
inadequ respons drug
prescrib either med thu far treatment hc
gener tetrabenazin lowest co-pay
need document trial gener medic first
must fail tetrabenazin austedo approv
action consist label
must fail therapi first
noth specif diagnosi hd
one approv effect treatment huntington diseas
appeal char note
austedo difficult author get approv
central pharmaci help assur coverag
use therapi prior
prior auth need mani insur
experi yet austedo
difficult obtain prior author step edit
number except per share data
share assoc co
net debt ebitda ratio
number except per share data
disclos ftf notabl pipelin
viagra sildenafil dec settlement exclus
viread tenofovir dec settlemnet exclus
reyataz atazanavir dec settlement exclus
byetta exenatid inj oct settlement exclus
effient prasugrel launch patent expiri oct
butran launch sept patent expir
nuvar appeal state patent valid pend approv
renvela assum approv pend approv
acanya jul settlement exclus approv
pazeo settlement may pend approv
exjad assum month patent expiri approv
moviprep settlement sept pend approv
solodyn feb feb launch specif strength approv
uceri assum patent invalid hold oct launch pend approv
letairi undisclos settlement assum month last patent pend approv
levitra assum month patent tent approv
restasi patent invalid await appeal assum launch pend approv
noxafil drt assum compound patent expir jul hold pend approv
zubsolv sept patent upheld court pend approv
latuda lost jan patent tent approv
rozerem undisclos settlement assum jul compound expiri approv
zyclara settlement jul pend approv
vigamox assum month patent expiri approv
abraxan ode exclus pend approv
absorica settlement dec pend approv
silenor settlement jan exclus approv
tarceva undisclos settlement assum may expiri polymorph patent pend approv
diclegi assum month patent expiri approv
atripla/truvada undisclos settlemnet assum last patent emtricitabin expir gate approv
rayo settlement approv
xopenex hfa assum month patent expiri pend approv
onglyza franchis patent upheld court pend approv
disclos ftf notabl pipelin sub-tot
number except per share data
asset held sale
sale reserv allow
liabil held sale
tax long-term liabil
senior note loan
number except per share data
adjust reconcil ni net cash oper
impair long-liv asset
net gain loss sale long-liv assets/invest
translat adjust due venezuela devalu
research develop process
impair equiti invest net
decreas increas work capit
sale purchas busi net cash acquir
proce sale long-liv asset invest
purchas properti plant equip capital-expenditure
purchas invest asset
net invest
dividend paid ordinari share
proce issuance/ purchas ordinari share net
proce issuanc prefer share net
dividend paid prefer share
dividend paid non-control interest
proce exercis option employe
purchas treasuri shares/ ordinari share
net financ
translat adjust cash cash equival
net chang equival
